Cumulus Neuroscience Presents Data at the International Society for CNS Clinical Trials and Methodology Autumn Conference and the 38th European College of Neuropsychopharmacology Congress

BELFAST, Northern Ireland, Oct. 13, 2025 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, presented data at the International Society for CNS Clinical Trials and Methodology (ISCTM) Autumn Conference and the 38^th European College of Neuropsychopharmacology (ECNP) Congress in Amsterdam, the Netherlands.

Traditional clinical trials for disorders and diseases of the central nervous system (CNS) like Major Depressive Disorder (MDD) and Alzheimer's Disease (AD) are long, costly and can be burdensome for participants. The NeuLogiq Platform was purpose-built by Cumulus in collaboration with 10 top biopharma companies to generate objective clinical quality data through frequent, repeated digital measurements collected in clinic or in the home setting. These data can provide study sponsors with critical data and insights that allow for earlier decision-making, resulting in cost savings.

 

 

The first poster, presented at ECNP, titled, "Deploying User-Friendly Portable EEG to Measure Response to a Novel Antidepressant with Resting and Task-Driven Neurophysiological Endpoints," reported interim data from a Phase 1b study conducted in partnership with Delix Therapeutics. The poster featured data evaluating the pharmacodynamics, safety, and tolerability of a novel neuroplastogen, DLX-001, in people with MDD. The Phase 1b study was designed to show early evidence of target engagement and neuroplastic effects of DLX-001 in patients with MDD, and used the proprietary NeuLogiq Platform to gather data via high-frequency repeated measurements of cognition and neurophysiology.

"We are pleased that this platform supported evaluation of target engagement and cognitive effects of DLX-001 - a novel neuroplastogen - in our Phase 1b study in individuals with MDD," said Dr. Aaron Koenig, Chief Medical Officer of Delix Therapeutics. "Low-burden markers like these compliment other traditional translational measures and show promise as scalable approaches for derisking clinical programs earlier in development."

On October 21^st, Dr. Aaron Koenig will join Brian Murphy, PhD, Co-founder and CSO of Cumulus Neuroscience, for a webinar titled "Neuropsychiatry Clinical Trials: Evolving with Portable EEG and Digital Endpoints," where the findings from the Delix DLX-001 Phase 1b study will be discussed in more detail. Click here to learn more.